Predictive low-glucose suspend system and glycemic variability,International Journal of Diabetes in Developing Countries

当前位置： X-MOL 学术 › Int. J. Diabetes Dev. Ctries. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Predictive low-glucose suspend system and glycemic variability
International Journal of Diabetes in Developing Countries ( IF 0.9 ) Pub Date : 2021-06-03 , DOI: 10.1007/s13410-021-00957-1
Ferda Evin , Aysun Ata , Eren Er , Günay Demir , Hafize Çetin , Yasemin Atik Altınok , Samim Özen , Şükran Darcan , Damla Gökşen

Introduction

Predictive low-glucose suspend (PLGS) system helps prevent hypoglycemia.

Aim

To evaluate the effect of PLGS therapy on GV and percentage of time in range (TIR), time below range (TBR), and time above range (TAR) in pediatric type 1 diabetic patients.

Method

HbA_1c, coefficient of variation (CV), standard deviation (SD), and percentage of TIR, TBR, and TAR were evaluated in type 1 diabetic (T1D) pediatric patients followed up between Jan 2016 and Mar 2020 using PLGS system.

Results

Mean ages of diagnosis and duration of diabetes were 6.7 ± 4.1 and 8.2 ± 4.3 years, respectively. Nineteen of the patients were male (46.3%) and 22 were female (53.7%). Twenty-two (53.7%) of the patients were using low-glucose suspend system and 19 (46.3%) were on multiple daily injection therapy (MDI). On PLGS therapy, the 3rd, 6th, 9th, and 12th months’ HbA_1c of patients were not different from previous years’ mean HbA_1c in all participants. In the 3rd, 6th, 9th, and 12th months of PLGS therapy, % of TIR were 65.34 ± 14.75%, 65.80 ± 14.67%, 66.58 ± 11.21%, and 70.04 ± 10.16%, respectively (p = 0.01). Although statistically insignificant, CV decreased from 36.33 to 34.30% and SD decreased from 60.14 to 58.60 in the 1-year follow-up period (p = 0.062 and p = 0.246).

Conclusion

With PLGS therapy, TIR was > 70% and the time spent in hypoglycemia was very low.

中文翻译：

预测性低葡萄糖悬浮系统和血糖变异性

介绍

预测性低葡萄糖悬浮 (PLGS) 系统有助于预防低血糖症。

目标

评估 PLGS 治疗对小儿 1 型糖尿病患者的 GV 和范围内时间百分比 (TIR)、范围内时间 (TBR) 和范围内时间 (TAR) 的影响。

方法

使用 PLGS 系统对 2016 年 1 月至 2020 年 3 月期间随访的 1 型糖尿病 (T1D) 儿童患者的HbA _1c、变异系数 (CV)、标准偏差 (SD) 以及 TIR、TBR 和 TAR 的百分比进行了评估。

结果

平均诊断年龄和糖尿病病程分别为 6.7 ± 4.1 和 8.2 ± 4.3 岁。19 名患者为男性（46.3%），22 名患者为女性（53.7%）。22 名 (53.7%) 患者正在使用低葡萄糖悬浮系统，19 名 (46.3%) 正在接受多次每日注射治疗 (MDI)。在 PLGS 治疗中，所有参与者第 3、6、9 和 12 个月的 HbA _1c与前几年的平均 HbA _1c没有差异。在 PLGS 治疗的第 3、6、9 和 12 个月，TIR 的百分比分别为 65.34 ± 14.75%、65.80 ± 14.67%、66.58 ± 11.21% 和 70.04 ± 10.16%。0.0 ( p =)。尽管统计上不显着，但在 1 年的随访期间，CV 从 36.33% 下降到 34.30%，SD 从 60.14 下降到 58.60（p= 0.062 和p = 0.246）。